{"filings":[{"id":2051400,"accession_number":"0001628280-26-052527","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2026-08-04T20:03:32+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira Q2 revenue $192.4M (+6% YoY); divests iovera° to Zimmer Biomet for up to $140M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenue $192.4M (+6% YoY); GAAP net income $4.7M ($0.12 EPS) vs net loss of $4.8M in Q2 2025.","EXPAREL net sales $147.8M (+3% YoY); ZILRETTA $32.6M (+4%); iovera $6.8M (+22%).","Completed divestiture of iovera° to Zimmer Biomet for up to $140M ($70M upfront + milestones); closed July 31, 2026.","UnitedHealthcare now provides separate reimbursement for EXPAREL, covering ~40M lives.","Updated FY2026 total revenue guidance to $735M-$760M (from $745M-$770M) reflecting iovera divestiture."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1342637,"accession_number":"0001628280-26-046136","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2026-06-30T11:31:57+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Pacira divests iovera business to Zimmer Biomet for up to $140M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront payment of $70M; potential milestone payments up to $70M through 2031.","66 employees (~8% of workforce) expected to be hired by Zimmer Biomet at close.","Pacira to use net proceeds to pay down senior secured revolving credit facility.","Parties to collaborate on advancing spasticity program; incremental compensation possible.","Transaction expected to close in Q3 2026, subject to customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1001036,"accession_number":"0001628280-26-042525","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2026-06-11T20:32:54+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Pacira stockholders elect all three company director nominees; 2011 stock incentive plan fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All three company nominees (Christie, Hirawat, Wiggans) elected with ~25-28M votes; dissident slate from DOMA defeated with ~4.6M votes.","2011 Stock Incentive Plan failed: 14.2M for, 18.4M against; requires >50% approval.","ESPP approved: 29.1M for, 3.5M against; share reserve increased by 800,000 shares.","Say-on-pay passed 19.5M for vs 13.1M against; 452K broker non-votes.","Board committee assignments updated; new chairs: Young (Audit), Yang (People/Comp), Christie (Nominating)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92615,"accession_number":"0001628280-26-028854","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira Q1 revenue $177M (+5% YoY); GAAP EPS $0.07, non-GAAP $0.60; FY guidance reiterated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $177.4M (+5% YoY); EXPAREL $143.3M (+5%), ZILRETTA $26.8M (+15%), iovera° $6.2M (+21%).","GAAP net income $2.9M ($0.07/diluted); non-GAAP net income $24.5M ($0.60/diluted); adjusted EBITDA $40.2M.","Repurchased 2.2M shares for $50M at avg $22.28; $100M remains under authorization through Dec 2026.","Completed ZILRETTA Phase 3 enrollment for shoulder OA; topline readout expected by end of 2026.","Reiterated FY 2026 guidance: EXPAREL $600-620M, total revenue $745-770M, non-GAAP gross margin 77-79%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":177376000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103570,"accession_number":"0001628280-26-012238","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira BioSciences reports Q4 2025 revenue of $196.9M, up 5%, and full-year 2026 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 total revenue $196.9M (5% increase vs Q4 2024); EXPAREL sales $155.8M (+5%)","Full-year 2025 revenue $726.4M; GAAP net income $7.0M vs net loss of $99.6M in 2024","Repurchased 5.9M shares for $150.0M in 2025; $150M remaining authorization through Dec 2026","2026 guidance: EXPAREL net sales $600-620M, total revenue $745-770M, gross margin 77-79%","Strategic partnership with LG Chem for EXPAREL in select Asian-Pacific markets; Samit Hirawat appointed to board"],"consensus_eps_estimate":null,"consensus_eps_actual":0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":726411000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103569,"accession_number":"0001628280-26-003717","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pacira BioSciences appoints Dr. Samit Hirawat (ex-BMS CMO) to its Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 9 to 10 members; Hirawat appointed as Class III director, effective immediately.","Hirawat brings >25 years industry experience; most recently CMO, EVP, Head of Global Drug Development at Bristol Myers Squibb.","Hirawat appointed to Science and Technology Committee; receives standard non-employee director compensation.","Board determined Hirawat is independent under Nasdaq listing standards; no related party transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103568,"accession_number":"0001628280-26-001335","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira reports preliminary 2025 revenue of $726.4M; EXPAREL sales record high with 7% volume growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $726.4M vs $701.0M in FY2024, up 3.6%.","Q4 EXPAREL net sales $155.8M (record) vs $147.7M in Q4 2024, 7% volume growth.","Full-year EXPAREL net sales $575.1M vs $549.0M (+4.8%); ZILRETTA flat at $116.6M.","Repurchased 2.0M shares for $50.0M in Q4; $150M remains under current authorization.","Preliminary unaudited; full Q4/fiscal 2025 results and guidance expected later in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":726411000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119833,"accession_number":"0001628280-25-050145","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira Q3 total rev $179.5M (+6% YoY); GAAP net income $5.4M vs loss; guides FY rev lower, gross margin higher","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $179.5M, up 6% YoY; EXPAREL $139.9M (volume +9% offset by mix and discounting).","GAAP net income $5.4M ($0.12/share) vs net loss of $143.5M in Q3 2024, which included $163.2M goodwill impairment.","Adjusted EBITDA $49.4M vs $54.7M; non-GAAP net income $31.8M ($0.72 diluted) vs $38.2M ($0.79) prior year.","FY2025 revenue guidance lowered to $725-735M from $730-750M; non-GAAP gross margin raised to 80-82% from 78-80%.","Repurchased 2.0M shares for $50M; $200M remaining on authorization; exclusive license of AMT-143 (ropivacaine) with $5M upfront."],"consensus_eps_estimate":null,"consensus_eps_actual":0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":529538000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136386,"accession_number":"0001396814-25-000100","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira Q2 2025 revenue $181.1M, GAAP net loss $4.8M; guidance updated, legal win $28.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $181.1M (+2% YoY); EXPAREL $142.9M, ZILRETTA $31.3M, iovera° $5.6M.","GAAP net loss $4.8M ($0.11/share) vs net income $18.9M in Q2 2024; non-GAAP net income $36.0M.","Received $28.3M from favorable court ruling on EXPAREL royalty repayment from RDF in July 2025.","New $300M five-year revolving credit facility replaces prior term loan; reduces interest expense 60bps in 2026.","2025 guidance: revenue narrowed to $730M-$750M; non-GAAP gross margin raised to 78-80%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":350022000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136385,"accession_number":"0001396814-25-000093","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["2.05","7.01","9.01"],"status":"ready","headline":"Pacira BioSciences cuts 71 jobs (8% of workforce); decommissions 45-liter EXPAREL suite in San Diego","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of 71 employees (~8% of total) from Technical Operations at San Diego Science Center Campus.","Pre-tax charges of $2.4M-$2.8M in Q3 2025 for employee termination benefits, plus $5.4M accelerated depreciation.","Decommissioning 45-liter manufacturing suite after bringing two larger 200+ liter suites online in San Diego and Swindon, UK.","Expects annual operating expense savings of ~$13 million from the reduction in force.","New large-scale suites produce bulk EXPAREL volumes approximately four-fold greater per batch, improving gross margins."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136384,"accession_number":"0001104659-25-065979","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Pacira enters $300M revolving credit facility, replaces prior term loan A","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$300M senior secured revolver matures July 3, 2030; includes $10M LC sublimit and $15M swingline.","Proceeds used to repay and terminate existing term loan A facility; no prepayment penalties.","Interest rates: SOFR + 2.50%-3.25% or base rate + 1.50%-2.25%, based on leverage ratio.","Facility secured by substantially all assets of Pacira and subsidiary guarantors.","Incremental facility capacity up to greater of $225M or 100% Consolidated EBITDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153536,"accession_number":"0001396814-25-000089","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Pacira shareholders approve 2.5M share increase to equity plan; say-on-pay fails","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Amended 2011 Plan adding 2,500,000 new shares for future grants.","Advisory say-on-pay resolution failed: 14,752,829 for, 22,595,202 against, 33,777 abstain.","Board will hold annual say-on-pay votes based on frequency vote (1 year: 35,312,982 votes).","Three Class II directors elected: Bigal, Lee, Young; no other director changes.","KPMG ratified as auditor for FY 2025 with 40,022,569 for, 352,947 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153535,"accession_number":"0001396814-25-000060","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira Q1 revenue $168.9M, net income $4.8M; EXPAREL exclusivity extended to 2039","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $168.9M (+1% YoY); GAAP net income $4.8M ($0.10) vs $9.0M ($0.19) a year ago.","EXPAREL net sales $136.5M (+3% YoY) with 7% daily volume growth; ZILRETTA $23.3M (-10%).","Patent litigation settled with Fresenius Kabi; limited-volume entry starts at high single-digit % of U.S. volume, exclusivity to 2039.","Court ruling eliminates EXPAREL royalty obligation to RDF; future payments stopped, repayment sought.","Reiterates FY2025 guidance: revenue $725-765M, non-GAAP gross margin 76-78%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":168923000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153534,"accession_number":"0001396814-25-000055","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Pacira Biosciences authorizes $300M share repurchase program through Dec 31, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved $300M stock buyback, effective immediately, replacing the May 7, 2024 program.","Repurchases may be made on open market or via privately negotiated transactions at management's discretion.","Program expires December 31, 2026; can be suspended or discontinued at any time by the company.","No obligation to repurchase any specific number of shares under the authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153533,"accession_number":"0001396814-25-000051","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Pacira settles EXPAREL patent litigation; Fresenius licensed to sell generic from early 2030","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement with Fresenius Kabi, eVenus, Jiangsu Hengrui resolves all patent suits over EXPAREL (bupivacaine liposome).","Fresenius gets license to sell volume-limited generic starting on confidential date in early 2030, before last patent expiry in 2044.","Volume-limited percentages start at high-single-digit, increase to low-thirties in 2033, capped at high-thirties for final three years.","Unlimited generic license granted no earlier than 2039.","Pacira pays Fresenius $7 million for expected litigation cost savings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172262,"accession_number":"0001396814-25-000048","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Pacira BioSciences adopts majority voting standard for uncontested director elections","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved Third Amended and Restated Bylaws effective March 12, 2025.","Majority voting applies to uncontested director elections; plurality retained for contested.","No other changes were made to the prior bylaws.","Change is effective immediately upon approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172261,"accession_number":"0001396814-25-000039","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira BioSciences: 2024 record rev $701M, GAAP net loss $99.6M on $163M impairment; FY2025 rev guide $725M-$765M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 rev $187.3M (+3% YoY); full-year rev $701.0M (+4%); EXPAREL $549M, ZILRETTA $118M, iovera $22.8M.","Full-year GAAP net loss $99.6M ($2.15 loss/share) includes $163.2M goodwill impairment; adjusted EBITDA $223.9M (+4%).","Non-GAAP net income $157.7M ($3.20 diluted); Q4 non-GAAP net income $44.3M ($0.91 diluted).","Acquired remaining 81% of GQ Bio for ~$32M net; adds genetic medicine platform, eliminates future milestones.","FY2025 guidance: rev $725-765M, non-GAAP gross margin 76-78%, R&D $90-105M, SG&A $290-320M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":700966000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172260,"accession_number":"0001396814-25-000022","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-01-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pacira BioSciences appoints Laura Brege as Board Chair; two directors retire","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul J. Hastings (former Chair) and Andreas Wicki retired effective Jan. 28, 2025; no disagreement cited.","Laura Brege appointed Chair; brings 30 years pharma/biotech executive experience.","Board reduced from 12 to 9 directors; 8 of 9 are independent; 5 joined since Oct. 2023.","Alethia Young succeeds Brege as Audit Committee Chair; other committee assignments refreshed.","Brege previously held leadership roles at BridgeBio, Onyx Pharmaceuticals, and COR Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172259,"accession_number":"0001396814-25-000017","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pacira appoints Brendan Teehan as CCO, Krys Corbett as CBO; adds 785K shares to inducement plan","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brendan Teehan named Chief Commercial Officer effective Jan 21, 2025; previously COO at Acadia Pharmaceuticals.","Krys Corbett appointed Chief Business Officer; most recently led portfolio strategy at Lyell Immunopharma.","Daryl Gaugler transitions from COO to EVP Commercial Operations; compensation and agreement unchanged.","Board adopted amended inducement plan adding 785,000 shares (total 2,310,000) and extending term to Jan 2035.","Company cites '5x30' strategy to grow commercial base and advance pipeline toward innovative biopharma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172258,"accession_number":"0001396814-25-000011","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira preliminary FY2024 revenue $701M (+3.9% YoY); announces 5x30 growth plan","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 total revenue of $701.0M, up from $675.0M in 2023; Q4 EXPAREL $147.7M.","EXPAREL net sales $549.0M, ZILRETTA $118.1M, iovera° $22.8M for full year.","Unveils 5x30 plan: treat >3M patients/year, double-digit revenue CAGR, 5pp gross margin improvement by 2030.","Inducement grants: options for 20,300 shares and RSUs for 30,400 shares at $18.40.","Revenue preliminary and unaudited; full Q4 and FY results with guidance expected Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":700966000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189254,"accession_number":"0001396814-24-000140","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Pacira Q3 revenue $168.6M, net loss $143.5M on $163.2M goodwill impairment; affirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $168.6M; EXPAREL $132.0M (+2.6%), ZILRETTA $28.4M, iovera° $5.7M.","GAAP net loss $143.5M ($3.11/sh) on $163.2M goodwill impairment; non-GAAP net income $38.2M.","Adjusted EBITDA $54.7M; cash $453.8M. FY 2024 guidance reaffirmed ($680M-$705M rev).","CMS final rule confirms separate NOPAIN reimbursement for EXPAREL/iovera° starting Jan 1, 2025; new J-code J0666 effective same date.","Executive employment agreements amended for Gaugler, Slonin, Williams: enhanced severance (12-mo salary continuation; 18-mo on change of control)."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":513713000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189253,"accession_number":"0001396814-24-000129","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2024-10-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pacira BioSciences appoints Shawn Cross as CFO effective Oct 21, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shawn Cross appointed CFO effective Oct 21, 2024; succeeds interim CFO Lauren Riker, who remains SVP of Finance.","Cross brings >25 years of biopharma experience; former CEO/President/CFO of Applied Molecular Transport.","Annual base salary $525K; annual bonus target 50% of base; inducement awards of 200K stock options and 75K RSUs.","Inducement awards vest over four years; option exercise price equals Nov 4, 2024 closing price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205751,"accession_number":"0001396814-24-000124","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pacira names Lauren Riker interim CFO; Reinhart departs Sept 30","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Charles Reinhart departs Sept 30, 2024; will serve as consultant for 9 months.","Lauren Riker, SVP of Finance, appointed interim CFO effective Oct 1, 2024.","Riker's base salary unchanged at $374,700; bonus target 50%; receives one-time $75k bonus.","Riker to serve as interim CFO until permanent successor identified.","No changes to existing employment agreement or other compensation terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205750,"accession_number":"0001396814-24-000120","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Pacira board rejects director Laura Brege's resignation after majority withhold vote","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Laura Brege received majority withhold votes at 2024 annual meeting; tendered resignation per company policy.","Independent directors unanimously rejected resignation after considering her qualifications, attendance, and prior support.","Brege stepped down from HLS Therapeutics board on Aug 7 to address overboarding; remains Pacira director until 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205749,"accession_number":"0001396814-24-000103","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pacira's EXPAREL patent invalidated by New Jersey court; company plans appeal","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["U.S. District Court for D.N.J. ruled Pacira's U.S. Patent No. 11,033,495 for EXPAREL is invalid.","Company intends to appeal the decision to the U.S. Court of Appeals for the Federal Circuit.","Three separate infringement suits against eVenus remain ongoing; additional patents pending.","CEO Frank D. Lee stated belief in patent strength and that EXPAREL franchise is well protected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205748,"accession_number":"0001396814-24-000097","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira Q2 2024: Revenue $178M, GAAP EPS $0.39; CMS proposes EXPAREL outpatient reimbursement under NOPAIN","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues of $178.0M, up 5% YoY; EXPAREL sales $136.9M (+1.3%), ZILRETTA $30.7M.","GAAP net income $18.9M ($0.39 diluted EPS) vs $25.8M ($0.51) in Q2 2023.","Non-GAAP net income $44.2M ($0.89 diluted EPS) vs $36.0M ($0.71) a year ago; adjusted EBITDA $62.1M.","CMS proposed rule would separately reimburse EXPAREL in HOPD/ASC starting Jan 2025 under NOPAIN Act.","Full-year 2024 revenue guidance reiterated at $680M-$705M; $150M share repurchase program ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":345140000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222703,"accession_number":"0001396814-24-000057","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Pacira BioSciences director Gary Pace to retire June 30; consulting deal; shareholder votes","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Gary Pace to retire from Board June 30, 2024; no disagreement with company.","Consulting agreement amendment: one-year term from July 2024 to June 2025, $3,200/quarter for up to 8 hours.","Shareholders elected Class I directors: Laura Brege, Mark Froimson, Mark Kronenfeld, Michael Yang.","KPMG ratified as independent auditor for FY 2024 with ~43.9M for, 0.2M against.","Advisory say-on-pay vote passed with ~37.2M for, 4.1M against, 2.7M broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222702,"accession_number":"0001104659-24-061135","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Pacira BioSciences issues $287.5M convertible notes, repurchases $200M of 2025 notes and $25M stock","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $250.0M (plus $37.5M option) of 2.125% Convertible Senior Notes due 2029; net proceeds ~$278.4M.","Used ~$191.4M to repurchase $200M aggregate principal of outstanding 0.750% convertible notes due 2025.","Used ~$25.0M to repurchase 837,240 shares of common stock.","Entered into capped call transactions to reduce potential dilution upon conversion, with cap price ~$53.75/share.","Initial conversion price ~$39.56/share, representing ~32.5% premium over closing price of $29.86 on May 9, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222701,"accession_number":"0001104659-24-058675","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Pacira proposes $250M convertible note offering due 2029; up to $50M share repurchase","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Proposed offering of $250M aggregate principal of Convertible Senior Notes due 2029, with initial purchasers' option for additional $37.5M.","Proceeds to repurchase portion of outstanding 0.750% 2025 Notes, fund capped call transactions, and repurchase up to $50M of common stock.","Capped call transactions expected to reduce dilution upon conversion and offset cash payments in excess of principal amount.","Entered First Amendment to Credit Agreement to permit $150M share repurchase program and the proposed note offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222700,"accession_number":"0001396814-24-000044","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Pacira Q1 net income $9.0M ($0.19 EPS); announces $150M share repurchase","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net income $9.0M ($0.19/sh) vs net loss $19.5M ($0.43 loss) YoY.","Total revenue $167.1M, up from $160.3M YoY; EXPAREL net sales $132.4M.","Adjusted EBITDA $44.6M vs $41.9M YoY; cash flow from ops $49.1M.","Board authorizes $150M share repurchase program through Dec 2026.","FY2024 guidance reaffirmed: revenue $680M-$705M, non-GAAP gross margin 74%-76%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":167117000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242191,"accession_number":"0001396814-24-000026","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Pacira BioSciences: FY2023 revenue $675M (+1% YoY), net income $42M; CFO to leave Sept 30","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $181.2M (+5% YoY), GAAP net income $24.9M ($0.54 basic EPS), adj EBITDA $65.4M.","Full-year 2023 total revenue $675.0M (+1% YoY), GAAP net income $42.0M ($0.91 basic EPS), adj EBITDA $214.5M.","CFO Charles Reinhart to depart effective Sept 30, 2024; transition services through June 2025; search for successor underway.","2024 guidance: total revenue $680M-$705M; non-GAAP gross margin 74%-76%; R&D $70M-$80M; SG&A $245M-$265M.","FDA approved new 200L EXPAREL manufacturing suite in Feb 2024; expects commercial product later this year to benefit gross margins."],"consensus_eps_estimate":null,"consensus_eps_actual":0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":674978000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242190,"accession_number":"0001396814-24-000010","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira reports preliminary FY2023 revenue of $675.0M, up 1.2% YoY; Q4 EXPAREL sales $143.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 total revenue $675.0M vs $666.8M in FY2022, driven by EXPAREL ($538.1M), ZILRETTA ($111.1M), iovera° ($19.7M).","Q4 2023 EXPAREL net sales $143.9M (+4.3% YoY); ZILRETTA $28.7M (+2.5%); iovera° $6.0M (+30%).","ExPAREL full-year average daily volume growth of 5%, offset by lower net selling price from 340B and other contracts.","Company plans to launch EXPAREL in two lower extremity nerve blocks in 2024 and expects NOPAIN Act expansion in 2025.","Preliminary, unaudited figures; complete Q4/FY results with 2024 guidance expected in Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":674978000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259600,"accession_number":"0001396814-23-000085","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pacira appoints Frank D. Lee as CEO effective Jan 2, 2024; Stack retires to advisory role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Frank Lee named CEO and Board member, effective Jan 2, 2024; prior CEO of Forma Therapeutics.","David Stack retires as CEO and Chairman, remains as advisor through August 2025.","Paul Hastings, Lead Independent Director, elected Chair of the Board effective Jan 2, 2024.","Lee's compensation: $900k base salary, 85% bonus target, 692,512 options, 99,520 RSUs as inducement awards.","Pacira Amended 2014 Inducement Plan to reserve 817,093 shares; term extended to Dec 20, 2033."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259599,"accession_number":"0001396814-23-000077","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira Q3 net income $10.9M, cuts FY EXPAREL guidance; CEO Stack to retire","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $163.9M, down ~2% YoY; EXPAREL sales $128.7M, down from $132.6M.","GAAP net income $10.9M ($0.23/sh) vs net loss $0.7M in Q3 2022; adjusted EBITDA $52.9M.","Lowers FY 2023 EXPAREL net product sales guidance to $535-540M from prior $550-560M.","CEO Dave Stack will retire; remains until successor appointed, then consulting through Aug 2025.","PDUFA action date for EXPAREL lower extremity nerve block on track for Nov 13, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":493734000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":259598,"accession_number":"0001396814-23-000056","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pacira BioSciences appoints four new independent directors, expanding board to 12","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from 10 to 12 directors; appointed Alethia Young (Audit), Marcelo Bigal (Science & Tech), Abraham Ceesay (Compensation), Michael Yang (Compensation).","All four are independent under Nasdaq standards; bring scientific, commercial, and financial expertise.","Appointments effective immediately; each receives standard non-employee director compensation.","Appointments enhance racial and gender diversity on the board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276865,"accession_number":"0001396814-23-000048","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pacira CEO David Stack to retire; board initiates search for successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stack will remain as CEO until successor is appointed, then serve as consultant through August 2025.","Entitled to base salary through Sept 1, 2024; continues equity vesting and bonus eligibility for 2023-2024.","Board retains Klein Hersh International to lead comprehensive CEO search.","Transition agreement includes non-disparagement, cooperation, indemnification, and consulting fee of $20k/month for up to 15 hours.","Press release issued September 26, 2023; retirement effective upon appointment of new CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276864,"accession_number":"0001396814-23-000045","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Pacira board rejects Gary Pace's resignation after withhold vote; plans diverse director additions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At June 13 annual meeting, Dr. Gary Pace received more withhold than for votes in Class III director election.","Pace tendered resignation per majority-vote policy; independent directors unanimously rejected it.","Board engaged independent search firm to identify diverse candidates; expects to refresh board composition soon.","Pace will continue as Class III director until 2026 annual meeting or until successor elected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":276863,"accession_number":"0001396814-23-000035","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira Q2 net income $25.8M; EXPAREL guidance cut to $550-560M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $169.5M flat YoY; EXPAREL net sales $135.1M down from $137.0M.","GAAP net income $25.8M ($0.51 diluted EPS) vs $19.9M ($0.40) YoY; adjusted EBITDA $54.3M.","Lowers FY2023 EXPAREL guidance to $550-560M from $570-580M; ZILRETTA to $110-115M.","Cash $220.8M; operating cash flow $43.5M vs $29.8M YoY.","Non-GAAP gross margin guidance cut to 73-74% from prior 76-78%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":329808000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294695,"accession_number":"0001396814-23-000029","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Pacira stockholders approve 3.3M share increase in equity plan; director Gary Pace faces significant withhold vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Amended 2011 Stock Incentive Plan, adding 3,300,000 new shares for future grants.","Gary Pace elected as Class III director with 16.1M for vs 23.9M withhold (40.3% support).","KPMG ratified as auditor for FY2023 with 41.9M votes for (99.3% of votes cast).","Advisory 'say-on-pay' vote approved with 34.6M for (86.5% of votes cast).","Plan approval vote: 24.1M for, 15.8M against (60.4% for, excluding broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294694,"accession_number":"0001396814-23-000020","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira Q1 total revenue $160.3M; net loss $19.5M; EXPAREL sales $130.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $160.3M vs $158.0M in Q1 2022, up 1.5%; GAAP net loss $0.43/share vs net income $0.15/share.","EXPAREL net product sales $130.4M, avg daily volumes up 6%, offset by 340B pricing; ZILRETTA $24.3M; iovera° $4.0M.","Adjusted EBITDA $41.9M vs $53.8M in Q1 2022; non-GAAP net income $24.3M ($0.53 diluted share).","FDA accepted sNDA for EXPAREL lower-extremity nerve blocks; PDUFA date Nov 13, 2023.","Repaid $287.5M Term Loan B using $150M new Term Loan A and cash; appointed Christopher Young Chief Manufacturing Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":160341000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":294693,"accession_number":"0001396814-23-000017","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2023-04-03T23:59:59+00:00","items":["1.01","1.02","2.03","8.01"],"status":"ready","headline":"Pacira refinances Term Loan B with $150M Term Loan A at 400 bps lower rate, cutting 2023 interest expense by $15M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repaid $287.5M Term Loan B outstanding using $150M new Term Loan A and cash on hand.","New Term Loan A matures March 2028; interest rate is SOFR + 3.00%-3.75%, 400 bps lower than prior facility.","Expects Q1 2023 cash and investments of approximately $180M after repayment.","Full-year 2023 interest expense reduction of at least $15M from lower rate.","CFO reaffirms 5-year plan for adjusted EBITDA margins exceeding 50% and improved leverage ratio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315291,"accession_number":"0001396814-23-000013","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["5.02","7.01"],"status":"ready","headline":"Pacira BioSciences announces director Yvonne Greenstreet to retire from board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Yvonne Greenstreet, independent director for 9 years, retiring effective March 31, 2023.","Greenstreet is CEO of Alnylam Pharmaceuticals; retirement not due to any disagreement.","Pacira will initiate search for an independent board member to replace her."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315290,"accession_number":"0001396814-23-000008","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira BioSciences reports record 2022 revenue of $667M; Q4 GAAP net loss widens to $10.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2022 revenue $666.8M (+23% YoY); GAAP net income $15.9M ($0.34 diluted EPS) vs $42.0M ($0.92) in 2021.","Q4 2022 revenue $172.0M (+8% YoY); GAAP net loss $10.1M ($0.22 loss per share) vs loss $5.1M in Q4 2021.","ZILRETTA net sales $105.5M full year; Q4 $28.0M (+121% YoY) driving growth. EXPAREL $536.9M (+6%) full year; Q4 $138.0M (-1%).","2023 guidance: EXPAREL net sales $570-580M, ZILRETTA $115-125M, non-GAAP gross margin 76-78%.","Submitted sNDA for EXPAREL sciatic/femoral nerve blocks; opened Houston Innovation & Training Center in Jan 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":666823000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":315289,"accession_number":"0001396814-23-000003","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2023-01-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira BioSciences reports preliminary 2022 revenue of $666.8M, up 23.1% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["EXPAREL net sales $536.9M in 2022 vs $506.5M in 2021; Q4 2022 sales $138.0M, roughly flat vs prior Q4.","ZILRETTA net sales $105.5M in 2022 vs $12.7M in 2021 (acquired Nov 2021); Q4 2022 sales $28.0M.","Adjusted EPS expected at least $2.50 for 2022, marking ninth consecutive year of positive adjusted earnings.","Prepaid $50M on Term Loan B in Dec 2022; plans another significant prepayment in 2023.","Management cites strong balance sheet, durable cash flows, and outperformance vs surgical market."],"consensus_eps_estimate":null,"consensus_eps_actual":0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":666823000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333630,"accession_number":"0001396814-22-000072","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2022-12-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira reports Nov 2022 preliminary net product sales of $57.5M; EXPAREL unit volumes up 4% YoY","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EXPAREL net sales $46.0M (99% of Nov 2021); unit volumes 104% of Nov 2021; selling days flat at 20.","ZILRETTA net sales $10.0M; iovera° net sales $1.5M (unchanged YoY).","Expanded contracting and 340B pricing expected to drive volume growth and be accretive in 2023.","No 2022 revenue or gross margin guidance provided due to COVID-19 and labor shortage uncertainty.","Company continues monthly intra-quarter sales reporting until visibility improves."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333629,"accession_number":"0001396814-22-000070","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira reports Oct 2022 preliminary net sales of $54.9M; EXPAREL average daily sales 106% of prior year","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited net product sales of $54.9M for October 2022.","EXPAREL net sales $45.0M (vs $42.5M Oct 2021); average daily sales 106% of prior year.","ZILRETTA net sales $8.6M (acquired Nov 2021); iovera° net sales $1.3M (vs $1.2M).","Company not providing FY2022 revenue/gross margin guidance due to COVID-19 uncertainty.","CEO Dave Stack reiterates confidence in double-digit growth and value creation from partnerships."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333628,"accession_number":"0001396814-22-000066","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira Q3 revenue up 31% to $167.5M, GAAP net loss $0.7M; EXPAREL sales $132.6M, patent to 2041","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $167.5M (+31% YoY); EXPAREL $132.6M (+9%), ZILRETTA $26.5M.","GAAP net loss $0.7M ($0.02 loss/share) vs prior-year net income $17.7M ($0.40).","Non-GAAP net income $29.9M ($0.65/share); adjusted EBITDA $55.2M vs $48.1M.","New EXPAREL composition patent (No. 11,452,691) expires Jan 2041; positive Phase 3 lower extremity nerve block results.","CHMP positive opinion for pediatric EXPAREL use; encouraging Phase 1 data for PCRX-201 gene therapy."],"consensus_eps_estimate":null,"consensus_eps_actual":0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":494868000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":333627,"accession_number":"0001396814-22-000059","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2022-10-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira reports preliminary Q3 2022 revenue of $167.5M, up 31% YoY; EXPAREL sales up 9%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited Q3 2022 revenue $167.5M vs $127.7M in Q3 2021.","EXPAREL net sales $132.6M (Q3 2022) vs $121.9M (Q3 2021); average daily sales 109% of prior year.","ZILRETTA net sales $26.5M for Q3 2022; iovera° net sales $4.5M.","Company not providing 2022 revenue or gross margin guidance due to macro uncertainty.","Monthly intra-quarter revenue disclosure continues; weekly EXPAREL utilization data posted on investor site."],"consensus_eps_estimate":null,"consensus_eps_actual":0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":494868000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351098,"accession_number":"0001396814-22-000057","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2022-09-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira reports preliminary August net product sales of $59.1M; EXPAREL up 13% YoY","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total net product sales of $59.1M for August 2022; EXPAREL $46.7M (vs $41.4M in Aug 2021).","EXPAREL average daily sales were 108% of Aug 2021; 23 selling days vs 22.","ZILRETTA contributed $9.7M; iovera° $1.5M (up from $0.9M); veterinary sales $1.2M.","More than 11 million patients have received EXPAREL since launch.","Company not providing 2022 revenue guidance due to COVID-19 and labor uncertainty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":351097,"accession_number":"0001396814-22-000055","cik":1396814,"company_name":"Pacira BioSciences, Inc.","ticker":"PCRX","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pacira reports July 2022 net product sales of $50.2M; EXPAREL daily sales up 5% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited net product sales for July 2022: $50.2M total ($40.9M EXPAREL, $8.2M ZILRETTA, $1.1M iovera°).","EXPAREL net sales flat vs. July 2021 at $40.9M, but average daily sales up 5% on 20 vs. 21 selling days.","ZILRETTA sales of $8.2M reflect continued early-stage growth; iovera° sales $1.1M vs. $1.0M prior year.","CEO cites expanding EXPAREL adoption; Phase 3 lower extremity nerve block results expected in Q3 and Q4 2022.","No FY2022 revenue or gross margin guidance provided due to ongoing COVID-19 and labor uncertainty."],"consensus_eps_estimate":null,"consensus_eps_actual":0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":327402000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":939122774.422837,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-10T23:59:59+00:00|351097"}